Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03267888 · ClinicalTrials.gov registry record · Phase 1
Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT03267888 is a Phase 1 study that has completed, run by Emory University. The registered enrollment target is 25 participants.
The verdict
NCT03267888, a Phase 1 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This pilot clinical trial studies the side effects of pembrolizumab and radiation therapy in treating patients with stage I-III multiple myeloma that has come back after a period of improvement or that does not respond to treatment. Monoclonal antibodies, such as pembrolizumab, may block cancer growth in different ways by targeting certain cells. Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. Giving pembrolizumab and radiation therapy may work better in treating patients with stage I-III multiple myeloma.
Interventions
- BIOLOGICAL Pembrolizumab
- RADIATION Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2018-05-29 |
| Est. Completion | 2022-09-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03267888
The ClinicalTrials.gov registry entry for NCT03267888 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03267888 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03267888 about?
NCT03267888 is a clinical study titled "Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma". This pilot clinical trial studies the side effects of pembrolizumab and radiation therapy in treating patients with stage I-III multiple myeloma that has come back after a period of improvement or that does not respond to treatment. Monoclonal antibodies, such as pembrolizumab, may block cancer grow...
What is the current status of trial NCT03267888?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2018-05-29. Estimated completion is 2022-09-02.
What interventions are being tested in trial NCT03267888?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT03267888?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.